Innovating Antibodies, Improving Lives

37th Annual J.P. Morgan Healthcare Conference January 9, 2019 Genmab



Forward Looking Statement

This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.



Building a Business that Transforms Cancer Treatment

Our Core Purpose, Strategy & Vision





Core Purpose To improve the lives of patients by creating & developing innovative antibody products



Strategy


- Turn science into medicine
- Build a profitable & successful biotech
 - Focus on Core
 Competence




By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks off antibodies




Track Record & Growth






Our Own Products in Clinical Development:





Innovation Powerhouse

The Genmab Difference



Y Creating value, transforming cancer treatment




Solid Foundation Built on Differentiated Pipeline

Foundational	Our own Clinical	2019 INDs*	Technologies
Products	Pipeline		& Pre-Clinical
 DARZALEX[®] Arzerra[®] Ofatumumab [RMS] 	 Tisotumab Vedotin Enapotamab Vedotin HexaBody[®]-DR5/DR5 DuoBody[®]-CD3xCD20 	 DuoHexaBody™-CD37 DuoBody[®]-CD40x4-1BB DuoBody[®]-PD-L1x4-1BB 	 DuoBody[®] HexaBody[®] HexElect[™] Rich pre-Clinical Pipeline
Solid Financial Base	Fueling Innovative	Accelerating	R&D
Significant Potential	Clinical Pipeline	Growth	Engine
Tr Tr			




Daratumumab (Marketed as DARZALEX®)

Reshaping Treatment of Multiple Myeloma Across All Lines of Therapy



Genmab

Daratumumab Efficacy in Newly Diagnosed Multiple Myeloma Phase III MAIA Trial (D+Rd): ASH Dec 2018



In D-Rd arm:

D = daratumumab

PFS = progression free survival

MRD – minimal residual disease

R = lenalidomide d = dexamethasone

- 44% reduction risk of disease progression or death in patients receiving D-Rd
- Median PFS not reached
 - >3-fold higher MRD-negative rate
 - Y2019 Filing & FDA Approval Anticipated


8



Daratumumab: Proving to be the Critical Driver Across Different Combinations & Treatment Lines

Frontline

Relapsed/Refractory




Dara containing regimen Standard of Care

Data as per ASH 2018 ¹Includes CR + sCR; ²At 10⁻⁵ sensitivity; ³Risk reduction in disease progression or death vs. control arm



Enhancing the Product: SC Formulation for Shorter Infusion Time Phase I PAVO Trial (daratumumab monotherapy)




Y 2019 – COLUMBA SC safety & efficacy analysis

Image is for representational purposes only & does not reflect actual syringe used



Ofatumumab (OMB 157)

Potential in Relapsing Multiple Sclerosis




Y 2019 – ASCLEPIOS I & II completion & reporting



Tisotumab Vedotin


Building Our Pipeline: Addressing a High Unmet Medical Need



Y 2019 – Ph II innovaTV 204 Cervical study enrollment completed




Tisotumab Vedotin Exploring Potential in Other Tumor Types





Enapotamab Vedotin

Building Our Pipeline: Potential in Solid Tumors








HexaBody-DR5/DR5 (GEN1029)

Building Our Pipeline: Technology Makes the Difference




Y 2019 – Initial dose escalation clinical data



DuoBody-CD3xCD20 (GEN3013)


Building Our Pipeline: Potential for Improved Efficacy & Safety



Y 2019 – Clinical data dose escalation cohorts



Building Our Pipeline: Next Wave of Clinical Products 2019 IND Targets – Targeted Investments



tumor sites

Unique mechanism-of-action

differentiated PD-L1 product



Key 2019 Priorities


Building a Robust Differentiated Product Portfolio

Priority	\checkmark	Targeted Milestones	
Daratumumab		 » FDA decision on Phase III MAIA & CASSIOPEIA multiple myeloma (MM) submission » Phase III COLUMBA MM subcutaneous (SC) daratumumab safety & efficacy analysis 	
Ofatumumab		» Phase III ASCLEPIOS I & II relapsing multiple sclerosis SC ofatumumab study completion and reporting	
Tisotumab Vedotin		» Phase II innovaTV 204 tisotumab vedotin recurrent / metastatic cervical cancer study enrollment complete by mid year	
Innovative pipeline		 Phase II enapotamab vedotin expansion cohort efficacy analysis Phase I/II HexaBody-DR5/DR5 initial clinical data Phase I/II DuoBody-CD3xCD20 clinical data dose escalation cohorts File INDs or CTAs for 3 new products 	



Delivering on Genmab's Promise

Innovating Antibodies, Improving Lives



19

Value

www.genmab.com